SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-320116
Filing Date
2021-11-04
Accepted
2021-11-04 16:02:06
Documents
14
Period of Report
2021-11-04
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d258571d8k.htm   iXBRL 8-K 41942
5 GRAPHIC g258571g1104211049874.jpg GRAPHIC 14370
6 GRAPHIC g258571gr001va1.jpg GRAPHIC 40918
  Complete submission text file 0001193125-21-320116.txt   302953

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tals-20211104.xsd EX-101.SCH 2883
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tals-20211104_lab.xml EX-101.LAB 18123
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tals-20211104_pre.xml EX-101.PRE 11399
7 EXTRACTED XBRL INSTANCE DOCUMENT d258571d8k_htm.xml XML 3355
Mailing Address 201 E. JEFFERSON ST., SUITE 110B LOUISVILLE KY 40202
Business Address 201 E. JEFFERSON ST., SUITE 110B LOUISVILLE KY 40202 502-569-1059
Talaris Therapeutics, Inc. (Filer) CIK: 0001827506 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40384 | Film No.: 211379816
SIC: 2836 Biological Products, (No Diagnostic Substances)